1 Correction to: PharmacoEconomics (2021) https://doi.org/10.1007/s40273-021-01098-3
The following sentence has been added to the end of the abstract of the original online version
“This decision was subsequently appealed, and an appeal decision has been reached.”
In the article, Sect. 3.2 Critique of Clinical Effectiveness Evidence and Interpretation, 5th para, 3rd and 4th sentences should be read as
“For example, the company did not provide a description of the methods used for the matching, except the process of selection of variables for which adjustment is required. Based on the provided information, it appeared that data were available for only three of the variables (disease type, number of prior systemic therapies, type of prior systemic therapies) that were considered in the analysis of the HES data and only one variable (disease type) was chosen for matching.”
In the article, Sect. 3.3 Cost‑Effectiveness Evidence Submitted by the Company, 14th para, final sentence should be removed.
“The impact of AEs on HRQoL was, however, not included in the model.”
The original article has been corrected.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
About this article
Cite this article
Grimm, S.E., Witlox, W., Wolff, R. et al. Correction to: Mogamulizumab for Previously Treated Mycosis Fungoides and Sézary Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics 40, 575 (2022). https://doi.org/10.1007/s40273-022-01144-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40273-022-01144-8